Retinoids for prevention and treatment of actinic keratosis

• Autor(a) principal: Ianhez, Mayra
• Data de Publicação: 2013
• Outros Autores: Miot, Hélio Amante [UNESP], Froes Fleury Junior, Luiz Fernando, Bagatin, Edileia
• Tipo de documento: Conjunto de dados
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP (dados de pesquisa)
• Texto Completo: http://dx.doi.org/10.1590/abd1806-4841.20131803; http://hdl.handle.net/11449/111485
• topic: Chemoprevention; Isotretinoin; Keratosis, Actinic; Retinoids; Tretinoin

Actinic keratosis is a common cause of dermatological consultations and it presents a strong association with squamous cell carcinoma. Many substances are used for treatment and prevention, such as retinoids. Nevertheless, many studies on retinoids emphasize their application in treating and preventing non melanoma skin cancers. In this article, we reviewed studies about systemic and topical retinoids used with immunocompetent patients and organ transplant recipients with actinic keratosis, as primary or secondary outcomes. The majority of these papers pointed to a reduction in actinic keratosis count after treatment with retinoids. However, studies need to be better-defined in order to address the lack of a standardized dose, the absence of control groups, the low number of patients and short follow-up periods. Blind, randomized and controlled clinical trials with adequate sample sizes, specifically focused on actinic keratosis, are needed to clarify the real benefit of topical and/or oral retinoids. Comparison of efficacy and safety between oral and topical retinoids in the prevention and treatment of non-melanoma skin cancers and actinic keratosis is an essential pre requisite to establish new strategies to control these conditions.